Physician profile
Michael Zadakis
NPI 1407548845
$3,340.90
in general payments reported to CMS, 2019-2025
17 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $916 · 2024: $981 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,340.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,003.30 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $678.48 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $604.73 | 2023-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Alkermes, INC. | $315.02 | 2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $200.61 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $170.59 | 2023-2025 | Uzedy, Austedo Xr |
| Indivior INC. | $68.85 | 2023-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $67.02 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $62.53 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $38.34 | 2023 | Quviviq |
| Angiodynamics, INC. | $36.18 | 2025 | Auryon Laser System 100-120 Vac |
| Xeris Pharmaceuticals, INC. | $22.88 | 2025 | Keveyis |
| Almatica Pharma LLC | $16.47 | 2025 | Loreev Xr |
| Noven Therapeutics, LLC | $14.37 | 2025 | Xelstrym |
| Lundbeck LLC | $14.12 | 2024 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $13.93 | 2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $13.48 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zadakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.